Proschmann U - Search Results

1

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.

Thomas K, Sehr T, Proschmann U, Rodriguez-Leal FA, Haase R, Ziemssen T. Thomas K, et al. Among authors: proschmann u. J Neuroinflammation. 2017 Feb 23;14(1):41. doi: 10.1186/s12974-017-0817-6. J Neuroinflammation. 2017. PMID: 28231856 Free PMC article.

2

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.

Sehr T, Proschmann U, Thomas K, Marggraf M, Straube E, Reichmann H, Chan A, Ziemssen T. Sehr T, et al. Among authors: proschmann u. J Neuroinflammation. 2016 Jun 27;13(1):164. doi: 10.1186/s12974-016-0635-2. J Neuroinflammation. 2016. PMID: 27349895 Free PMC article.

3

Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

Rodriguez-Leal FA, Haase R, Thomas K, Eisele JC, Proschmann U, Schultheiss T, Kern R, Ziemssen T. Rodriguez-Leal FA, et al. Among authors: proschmann u. Mult Scler. 2018 Sep;24(10):1337-1346. doi: 10.1177/1352458517720043. Epub 2017 Jul 25. Mult Scler. 2018. PMID: 28741976

4

Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

Sehr T, Proschmann U, Thomas K, Ziemssen T. Sehr T, et al. Among authors: proschmann u. Mult Scler. 2018 May;24(6):820-822. doi: 10.1177/1352458517726384. Epub 2017 Aug 14. Mult Scler. 2018. PMID: 28805095 No abstract available.

5

Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.

Thomas K, Proschmann U, Ziemssen T. Thomas K, et al. Among authors: proschmann u. Expert Opin Pharmacother. 2017 Oct;18(15):1649-1660. doi: 10.1080/14656566.2017.1373093. Epub 2017 Sep 4. Expert Opin Pharmacother. 2017. PMID: 28844164 Review.

6

Natalizumab during pregnancy and lactation.

Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Proschmann U, et al. Mult Scler. 2018 Oct;24(12):1627-1634. doi: 10.1177/1352458517728813. Epub 2017 Aug 31. Mult Scler. 2018. PMID: 28857686

7

Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Proschmann U, Akgün K, Ziemssen T. Proschmann U, et al. Neurology. 2018 Oct 30;91(18):849-850. doi: 10.1212/WNL.0000000000006422. Neurology. 2018. PMID: 30373924 No abstract available.

8

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.

Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K. Kaufmann M, et al. Among authors: proschmann u. Front Immunol. 2018 Nov 20;9:2669. doi: 10.3389/fimmu.2018.02669. eCollection 2018. Front Immunol. 2018. PMID: 30524432 Free PMC article.

9

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.

Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akgün K. Kaufmann M, et al. Among authors: proschmann u. Front Neurol. 2018 Dec 7;9:1071. doi: 10.3389/fneur.2018.01071. eCollection 2018. Front Neurol. 2018. PMID: 30581413 Free PMC article.

10

Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".

Proschmann U, Sehr T, Akgün K, Ziemssen T. Proschmann U, et al. Mult Scler. 2020 May;26(6):741-742. doi: 10.1177/1352458519837702. Epub 2019 Apr 3. Mult Scler. 2020. PMID: 30943104 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters